Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

Table 4

Numbers of AEs reported during chloroquine therapy and primaquine therapy.

Adverse event	Chloroquine therapy; total ()	Primaquine therapy
		P 15 mg; ()	PSR 15 mg; ()	PSR 30 mg; ()	Total; ()
Malaise	2	3	4	1	8
Headache	4	1	2	2	5
Nausea	12	2	1	1	4
Decreased appetite	8	0	3	0	3
Pyrexia	1	1	1	1	3
Vomiting	5	1	1	1	3
Dizziness	0	0	1	1	2
Myalgia	0	2	0	0	2
Asthenia	0	0	1	1	2
Arthralgia	0	0	1	0	1
Pruritus	5	0	0	1	1
Haemoglobin decreased	0	0	0	1	1
Muscle spasms	0	0	1	0	1
Dyspnoea exertional	0	0	1	0	1
Dyspepsia	0	0	0	1	1
Diarrhoea	0	0	1	0	1
Diarrhoea	1	0	0	0	0
Cough	1	0	0	0	0
Total events	39	10	18	11	39
Total patients, (%)	23 (6.4)	5 (4.2)	10 (8.5)	6 (5.0)	21 (5.9)

P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg.
value: P 15 mg versus PSR 15 mg (), P 15 mg versus PSR 30 mg (), and PSR 15 mg versus PSR 30 mg () (for patients reporting adverse events).